Ashvattha therapeutics to present phase 2 dme and wet amd data at clinical trials at the summit and maculart

Ashvattha will present phase 2 data on migaldendranib, a subcutaneous therapy for dme and wet amd, which could offer a more patient-friendly alternative to current injection-based treatments
AMD Ratings Summary
AMD Quant Ranking